Menopur is the one menotropins product still marketed in the United States. Menotropins are a glycoprotein hormone preparation, not a peptide, so the peptide sources on this site do not cover it. For the urinary hCG products that are often compared with it, see the hCG side effects page and the hCG vs hMG comparison. Its side effects are documented in a US label with trial tables, which is more than many fertility drugs give, and this page sets those tables out without adding anything the label does not state.
The IVF trial table
The label's main table comes from a trial of 434 women undergoing IVF or ICSI, and it lists every reaction that occurred in 2% or more of them on or after the GnRH step of treatment.
| Reaction, per the Menopur label (IVF and ICSI, n=434) | Share of women |
|---|---|
| Abdominal pain | 6.7% |
| Headache | 6.2% |
| Ovarian hyperstimulation syndrome (OHSS) | 6.2% |
| Injection-site pain and reaction | 3.9% |
| Abdominal cramps | 3.0% |
| Abdomen enlarged | 2.3% |
| Injection-site inflammation | 2.3% |
The label adds that thrombophlebitis occurred in fewer than 1% of women. Two other trials in the label describe their own reaction lists. In an open-label trial where Menopur and Bravelle were given in the same syringe to 60 women, OHSS, post-retrieval cramping, nausea and spontaneous abortion were the most common reactions at 5% or more. In a trial of 76 women with anovulatory or oligovulatory infertility, the reactions at 5% or more were headache, OHSS, injection-site reaction, abdominal cramps, fullness and pain, and nausea.
The warnings the label names
Section 6 of the label lists serious adverse reactions that are discussed in its warnings section. They are abnormal ovarian enlargement, ovarian hyperstimulation syndrome, atelectasis, acute respiratory distress syndrome and exacerbation of asthma, thromboembolic events, ovarian torsion, multiple pregnancy and birth, congenital malformations, ectopic pregnancy and spontaneous abortion.
Ovarian hyperstimulation is the reaction with the most trial data behind it in this label, because it appears in both the IVF table and the ovulation-induction trial. Thromboembolic events and ovarian torsion appear only as named warnings, with no trial rate in the adverse-reaction table.
The postmarketing list
After approval, the label lists reactions reported voluntarily from a population of unknown size, which means no frequency can be calculated from them. They include abdominal pain, abdominal distension, nausea, vomiting and injection-site reactions. The label states that the frequency of these, or their link to Menopur, cannot be reliably determined.
What is not established
- The trial rates come from treatment cycles in women. The label does not give rates for men, and this page reports none.
- The table gives how often each reaction occurred in trials, not how severe it was. This page does not add a severity split that the label does not give.
- The trial tables cover treatment cycles. The label's tables do not report outcomes beyond those cycles, and this page adds none.
- The label does not report a rate for multiple pregnancy in its table, so this page does not state one.
- This page did not open FDA's adverse-event database for Menopur. Any figure from it would need its own dated check.
Who makes the decisions
Decisions about these reactions, including whether treatment is appropriate and how it is monitored, belong to the prescribing clinician. This page describes the label and does not replace it.
Sources and dates
- Menopur (menotropins) for injection, Ferring Pharmaceuticals, US prescribing information, DailyMed listing, listed 11 May 2026. Read on 9 November 2026. Sections 6.1 (trial tables) and 6.2 (postmarketing) and the warnings list in section 6 are the basis for every figure above.
